These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 12205349)
1. Is zero enough? Gonschior P J Invasive Cardiol; 2002 Sep; 14(9):514. PubMed ID: 12205349 [No Abstract] [Full Text] [Related]
2. Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. Huang Y; Liu X; Wang L; Verbeken E; Li S; De Scheerder I Int J Cardiovasc Intervent; 2003; 5(3):166-71. PubMed ID: 12959735 [TBL] [Abstract][Full Text] [Related]
4. Optimization of local methylprednisolone delivery to inhibit inflammatory reaction and neointimal hyperplasia of coated coronary stents. Huang Y; Wang L; Verweire I; Qiang B; Liu X; Verbeken E; Schacht E; De Scheerder I J Invasive Cardiol; 2002 Sep; 14(9):505-13. PubMed ID: 12205348 [TBL] [Abstract][Full Text] [Related]
5. Drug-eluting stents for the prevention of restenosis: Standing the test of time. Carter AJ Catheter Cardiovasc Interv; 2002 Sep; 57(1):69-71. PubMed ID: 12203932 [No Abstract] [Full Text] [Related]
11. Drug eluting stents for everyone and everything? Laham RJ Catheter Cardiovasc Interv; 2005 Dec; 66(4):512-3. PubMed ID: 16270362 [No Abstract] [Full Text] [Related]
12. Is the end of restenosis the beginning of a new era? Moses JW Ital Heart J; 2004 Feb; 5(2):81-4. PubMed ID: 15086136 [No Abstract] [Full Text] [Related]
13. Sirolimus-eluting stent implantation in a heart transplant recipient. Tomai F; Gagliardi G; Proietti I Ital Heart J; 2004 May; 5(5):408-9. PubMed ID: 15185909 [No Abstract] [Full Text] [Related]
14. Promise and challenges of bioabsorbable stents. Waksman R Catheter Cardiovasc Interv; 2007 Sep; 70(3):407-14. PubMed ID: 17722019 [TBL] [Abstract][Full Text] [Related]
15. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Kollum M; Farb A; Schreiber R; Terfera K; Arab A; Geist A; Haberstroh J; Wnendt S; Virmani R; Hehrlein C Catheter Cardiovasc Interv; 2005 Jan; 64(1):85-90. PubMed ID: 15619311 [TBL] [Abstract][Full Text] [Related]
16. Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Liu X; Huang Y; Hanet C; Vandormael M; Legrand V; Dens J; Vandenbossche JL; Missault L; Vrints C; De Scheerder I Catheter Cardiovasc Interv; 2003 Oct; 60(2):172-8; discussion 179. PubMed ID: 14517920 [TBL] [Abstract][Full Text] [Related]
17. Mycophenolic acid-eluting stent and the ABC's of stent-based immunosuppressive therapies for the prevention of restenosis. Carter AJ Catheter Cardiovasc Interv; 2005 Dec; 66(4):496-8. PubMed ID: 16283681 [No Abstract] [Full Text] [Related]
18. Drug-eluting stents. Med Lett Drugs Ther; 2003 Mar; 45(1152):23-4. PubMed ID: 12637894 [No Abstract] [Full Text] [Related]
19. Update on bioabsorbable stents: from bench to clinical. Waksman R J Interv Cardiol; 2006 Oct; 19(5):414-21. PubMed ID: 17020566 [TBL] [Abstract][Full Text] [Related]
20. Polymer coating techniques for drug-eluting stents. al-Lamee K; Cook D Med Device Technol; 2003; 14(1):12-4. PubMed ID: 12974119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]